title: Meta-analysis: risk of esophageal adenocarcinoma with medications which relax the lower esophageal sphincter.
abstract: Reasons for the rising annual incidence of esophageal adenocarcinoma (EAC) remain uncertain. Previous studies have given conflicting results, but some have suggested that drugs which relax the lower esophageal sphincter (LES) may increase the risk of EAC. This study is to determine systematically the risk of EAC associated with individual medications which relax the LES and compare risks with esophageal squamous cell carcinoma (ESCC) and gastric cardia adenocarcinoma (GCA). Relevant published studies were identified by systematic searching PubMed for case-control studies reporting on risk of EAC, ESCC or GCA with use of medications known to reduce LES pressure. Pooled odds ratios (ORs) were calculated for each malignancy. Data were analyzed from four case-control studies involving 9,412 participants. EAC was significantly associated with theophylline use (OR 1.55, 95% confidence interval [CI] 1.05-2.28; P= 0.03, I(2) = 0%) and anticholinergic medications (OR 1.66, 95% CI 1.13-2.44; P= 0.01, I(2) = 84%). This effect was not observed in cases of ESCC or GCA. Other drug groups including calcium channel modulators and nitrates did not increase the risk of EAC. An inverse relationship was observed between ESCC and nitrates and between GCA and benzodiazepines. The lack of increased EAC risk with many commonly used medications is reassuring. However, a significant correlation was found between EAC and the use of anticholinergics and theophyllines. This may reflect common causality between obstructive lung disease and EAC, and further studies to explore these relationships are warranted.
authors: Department of Gastroenterology, Norfolk and Norwich University Hospital, Norwich, UK.
authors: L
authors: L
authors: Alexandre
authors: T
authors: T
authors: Broughton
authors: Y
authors: Y
authors: Loke
authors: I L P
authors: IL
authors: Beales
mesh_terms: D000230:Adenocarcinoma / Q000453:epidemiology*; D000318:Adrenergic beta-Agonists / Q000627:therapeutic use; D001569:Benzodiazepines / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000453:epidemiology*; D002299:Cardia; D018680:Cholinergic Antagonists / Q000627:therapeutic use; D004938:Esophageal Neoplasms / Q000453:epidemiology*; D049630:Esophageal Sphincter, Lower / Q000187:drug effects*; D006801:Humans; D020030:Nitric Oxide Donors / Q000627:therapeutic use; D016017:Odds Ratio; D012306:Risk; D012307:Risk Factors; D013274:Stomach Neoplasms / Q000453:epidemiology*; D013806:Theophylline / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000627:therapeutic use
chemical_list: D000318:Adrenergic beta-Agonists; D002121:Calcium Channel Blockers; D018680:Cholinergic Antagonists; D020030:Nitric Oxide Donors; D014665:Vasodilator Agents; D001569:Benzodiazepines; D013806:Theophylline